Critical Assessment of the Status of Biomarkers for Alzheimer’s disease

Journal Title: Journal of Parkinson’s Disease and Alzheimer’s Disease - Year 2014, Vol 1, Issue 1

Abstract

Objective: We undertook a critical analysis of the status of the progress in the development of biomarkers for the detection of Alzheimer’s disease (AD). Methods: Biomarker studies involving imaging, metabolomics, lipidomics, proteomics, transcriptomics and microRNAs were assessed from publications between 2004 and 2014. Results: Extensive efforts have been applied to the development of minimally invasive and inexpensive assays for the early detection of AD. However, the failure to replicate findings between laboratories has presented a significant challenge in validating assays for clinical use. Larger scale studies and collaborations are required to standardize sample collection and storage, analytical methodology, and to control for heterogeneity in the AD patient population. Conclusions: Since cognitive testing cannot detect the presymptomatic stages of AD, validated biomarkers are essential for advancing both AD research and clinical practice. Despite intensive research over the last 10 years, there currently are no validated biomarkers for the early detection of AD.

Authors and Affiliations

Paul L. Wood

Keywords

Related Articles

Cerebrovascular and Blood-Brain Barrier Compromise: A Mechanistic Link between Vascular Disease and Alzheimer’s Disease Subtypes of Neurocognitive Disorders

Alzheimer’s disease (AD) and vascular dementia (VaD) are the most common subtypes of neurocognitive disorders (NCDs), with overlapping clinical presentation and risk factors. Studies on AD brains have demonstrated increa...

Therapeutic Advantages of Dual Targeting of PPAR-δ and PPAR-γ in an Experimental Model of Sporadic Alzheimer’s Disease

Background: Alzheimer’s disease (AD) is associated with progressive impairments in brain responsiveness to insulin and insulinlike growth factor (IGF). Although deficiencies in brain insulin and IGF could be ameliorated...

Medical Driving Assessment Outcomes in Seniors Using The KSCAr+Drive: An In-Office Screening Tool to Assist Clinicians in Determining Driving Safety and Who to Refer for Medical Driving Assessments

Objectives: The purpose of this study was to examine how the KSCAr might be utilized to help identify seniors with MCI/Dementia as safe vs. unsafe to drive, or for whom referral to a medical driving assessment was requir...

Isoflurane in the Aged Brain: A Link to Altered Amyloid Precursor Protein Processing

General anaesthesia can cause an altered mental status, particularly in elderly patients. While these changes usually represent a temporary, reversible delirium, there is growing, but still inconclusive evidence that sug...

Two Patients with Migraine and Parkinsonism: A Possible Relationship?

Migraine is linked to an increased occurrence of neurological movement disorders including Parkinsonism. We describe two women with chronic, severe migraine with aura who later in life developed Parkinsonism. In both cas...

Download PDF file
  • EP ID EP207461
  • DOI 10.13188/2376-922X
  • Views 115
  • Downloads 0

How To Cite

Paul L. Wood (2014). Critical Assessment of the Status of Biomarkers for Alzheimer’s disease. Journal of Parkinson’s Disease and Alzheimer’s Disease, 1(1), 1-4. https://europub.co.uk/articles/-A-207461